SYROS PHARMACEUTICALS, INC.

Analyst Reco. Syros Pharmaceuticals, Inc.

Equities

SYRS

US87184Q2066

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
5.13 ^USD	-1.35%		+1.79%	-34.15%

09/04	Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	MT
09/04	Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JMP Securities Adjusts Price Target on Syros Pharmaceuticals to $15 From $16, Maintains Market Outperform Rating	11/23/11	MT
Oppenheimer Adjusts Syros Pharmaceuticals Price Target to $13 From $15, Maintains Outperform Rating	03/23/03	MT
Piper Sandler Cuts Price Target on Syros Pharmaceuticals to $20 From $27, Reiterates Overweight Rating	05/23/05	MT
Oppenheimer Adjusts Syros Pharmaceuticals Price Target to $15 From $30, Maintains Outperform Rating	15/22/15	MT
JMP Securities Cuts Price Target on Syros Pharmaceuticals to $16 From $40, Maintains Market Outperform Rating	15/22/15	MT
Oppenheimer Adjusts Syros Pharmaceuticals Price Target to $3 From $9, Maintains Outperform Rating	10/22/10	MT
HC Wainwright Adjusts Price Target on Syros Pharmaceuticals to $6 From $10, Reiterates Buy Rating	12/22/12	MT
HC Wainwright Adjusts Price Target on Syros Pharmaceuticals to $10 From $15, Reiterates Buy Rating	17/22/17	MT
Alliance Global Adjusts Price Target on Syros Pharmaceuticals to $10 From $14, Reiterates Buy Rating	17/22/17	MT
SYROS PHARMACEUTICALS : Roth Capital Adjusts Price Target on Syros Pharmaceuticals to $23 From $20, Maintains Buy Rating	23/21/23	MT
SYROS PHARMACEUTICALS : Oppenheimer Adjusts Syros Pharmaceuticals PT to $9 From $13, Maintains Outperform Rating	21/21/21	MT
SYROS PHARMACEUTICALS : Wedbush Adjusts Syros Pharmaceuticals' Price Target to $8 From $10, Maintains Neutral Rating	07/20/07	MT
SYROS PHARMACEUTICALS : HC Wainwright Upgrades Syros Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $15 From $11	04/20/04	MT
Syros Pharmaceuticals Announces New Data from Phase 2 Trial of SY-1425 in Combination with Azacitidine Demonstrating High Response Rates, Rapid Onset of Action and Favorable Tolerability Profile in RARA-Positive Newly Diagnosed Unfit AML Patients	24/19/24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer